azacitidine has been researched along with Monosomy in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouronikou, E; Diamantopoulos, P; Galanopoulos, AG; Hatzimichael, E; Kontos, CK; Kotsianidis, I; Megalakaki, A; Mparmparousi, D; Panayiotidis, P; Papadaki, H; Papageorgiou, SG; Pappa, V; Poulakidas, E; Symeonidis, A; Vasilatou, D; Vassilakopoulos, TP; Viniou, NA; Zikos, P | 1 |
| Auberger, P; Cassuto, JP; Cluzeau, T; Gabriel Fuzibet, J; Garnier, G; Gastaud, L; Gutnecht, J; Karsenti, JM; Legros, L; Montagne, N; Mounier, N; Raynaud, S; Re, D; Richez, V | 1 |
| Aul, C; Baron, F; Becker, H; Bogatyreva, L; de Witte, T; Ganser, A; Germing, U; Giagounidis, A; Hagemeijer, A; Huls, G; Labar, B; Lübbert, M; Marie, JP; Muus, P; Pflüger, KH; Platzbecker, U; Rüter, B; Salih, HR; Schaefer, HE; Selleslag, D; Suciu, S; van der Helm, L; Vellenga, E; Wijermans, PW | 1 |
| Batz, C; Flotho, C; Furlan, I; Lübbert, M; Mohr, B; Niemeyer, CM; Suttorp, M | 1 |
| Braulke, F; Haase, D; Jung, K; Schanz, J; Schuetze, C; Schulte, K; Shirneshan, K; Steffens, R; Trümper, L | 1 |
| Adès, L; Beyne-Rauzy, O; Boehrer, S; Dreyfus, F; Eclache, V; Fenaux, P; Gardin, C; Itzykson, R; Quesnel, B; Recher, C; Thépot, S; Turlure, P; Vey, N | 1 |
| Haas, PS; Lübbert, M; Verhoef, G; Wijermans, P | 1 |
| Claus, R; Kunzmann, R; Lübbert, M; Rüter, B; Wijermans, P | 1 |
3 trial(s) available for azacitidine and Monosomy
| Article | Year |
|---|---|
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Disease-Free Survival; Female; Germany; Humans; Leukemia; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Risk Factors | 2016 |
Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosomal Instability; Chromosome Deletion; Cytogenetic Analysis; Decitabine; Female; Follow-Up Studies; Humans; Male; Metaphase; Middle Aged; Monosomy; Myelodysplastic Syndromes | 2006 |
Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 7; Decitabine; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukocyte Count; Monosomy; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Time Factors; Treatment Outcome | 2007 |
5 other study(ies) available for azacitidine and Monosomy
| Article | Year |
|---|---|
The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cell Transformation, Neoplastic; Female; Greece; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Female; Humans; Karyotype; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome | 2013 |
Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Calcitonin; Chromosomes, Human, Pair 7; Clone Cells; Combined Modality Therapy; CpG Islands; DNA Methylation; Genes, ras; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myelomonocytic, Juvenile; Male; Monosomy; Neoplasm Proteins; Point Mutation; Promoter Regions, Genetic; Protein Precursors; Remission Induction | 2009 |
FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Azacitidine; Bone Marrow Cells; Chromosome Aberrations; Chromosomes, Human, Pair 7; Female; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes | 2010 |
Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.
Topics: Antimetabolites; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Compassionate Use Trials; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotyping; Monosomy; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Treatment Outcome | 2011 |